Amgen starts human testing on its own version of a GLP-1 drug

Amgen has begun human trials of a new GLP-1-type drug called maritide in people with Type 2 diabetes. This matters because Amgen is one of the largest drugmakers in the world, and its entry into this drug class could shape what happens next for patients who rely on GLP-1 medications. More companies testing similar drugs can eventually lead to more choices and, over time, lower prices. The trial is still in early stages, so maritide is not available to the public yet.

The study is officially called maridebart cafraglutide, and it is currently in Phase 2 of testing, with the trial listed as active but no longer recruiting new participants. That means Amgen has already enrolled enough people with Type 2 diabetes to move forward with data collection and analysis. Phase 2 trials are designed to test whether a drug works as intended and to look more closely at safety, so results from this stage will help determine whether Amgen moves toward larger, later-stage trials. For now, the drug remains in the research pipeline, and there is no timeline included in the record for when it might become available outside of a clinical trial setting. Anyone interested in following its progress can track the trial through its official listing, linked above.

If you take one thing from this update, it is that more competition among GLP-1 drugmakers is generally good news for patients, even if it takes time to reach them. A second major company entering this drug class suggests that current shortages and high prices may not be permanent conditions. I would suggest checking back on this trial's status periodically, especially if you are curious about how new treatments move from early testing to public availability. For now, maritide remains a research drug, not a treatment you can access, so patience is the right approach while Amgen collects and reviews its Phase 2 data.

By Amanda Bonello